Assay to study the pharmacokinetics-pharmacodynamics relationship in oncology
CompanyCN-BIO, Cambridge, United Kingdom
Modelling human tissue-specific biology and accurately predicting tumor response to human pharmacokinetic (PK) profiles in vitro is challenging. Therefore, poor correlation between preclinical PK and pharmacodynamic parameters and clinical studies is one reason for high drug failure rates.
CN-BIO's in vitro assay uses a microphysiological system (MPS), the PhysioMimix™ PK, which administers time-varying drug concentrations to human 3D tumor models, exposing them to a PK profile rather than a static concentration. Drug combinations, personalized medicine, dose schedules and PK/PD relationships can be tested in this way.
Until now, the effects of PK could only be studied in silico or in vivo. With the PhysioMimix oncology PK assay, the relationship between PK, PD and efficacy can be studied on a large scale in the laboratory for any 2D or 3D cell line, organoid or patient-derived tumor model.
What’s the alternative to Xenograft models in Oncology?
www.cn-bio.com
Added on: 03-16-2023
[1] https://cn-bio.com/applications/disease-modeling/oncology/
